Free Trial
→ A free stock pick, from me to you (From Behind the Markets) (Ad)tc pixel
NASDAQ:NXTC

NextCure Q3 2026 Earnings Date & Estimates

NextCure logo
$5.49 -0.82 (-12.98%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NextCure is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from NextCure in Q3 2026

NextCure is expected to post earnings of -$0.90 per share. In the same quarter a year earlier NextCure reported -$3.22 per share. NextCure last reported on August 6, 2026, posting -$2.80 per share and missing the -$1.95 consensus estimate. NextCure has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.90
Prior-Year EPS
-$3.22

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.80 (Missed by -$0.85)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

NextCure Q3 2026 Earnings FAQ

NextCure (NASDAQ:NXTC) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

NextCure's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect NextCure to post earnings of -$0.90 per share for Q3 2026.

NextCure Earnings Headlines

NextCure (NXTC) Expected to Post Quarterly Earnings on Monday
November 1 at 3:57 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31171690
NextCure CMO Departs Amid Pending Avere Merger
October 30 at 8:30 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nextcure-cmo-departs-amid-pending-avere-merger?utm_source=marketbeat.com&utm_medium=referral
The most dangerous moment in a financial crisis
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
November 2 at 1:00 AM  |  Weiss Ratings (Ad)
NextCure Faces Court Review of Reverse Stock Split
September 28, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NXTC/pressreleases/4818172/nextcure-faces-court-review-of-reverse-stock-split/
NextCure Ends Beltsville Lease to Cut Operating Costs
September 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nextcure-ends-beltsville-lease-to-cut-operating-costs?utm_source=marketbeat.com&utm_medium=referral
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
August 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/avere-therapeutics-announces-500-million-private-placement-to-support-development-of-once-weekly-oral-il-23-therapy-avr-001-302846694.html
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC) (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations. Michael Richman has served as the company’s chief executive officer and has been involved in its development as a biotechnology business.

View NextCure Profile
Earnings Tools